MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

XenoPort Company Profile (NASDAQ:XNPT)

Consensus Ratings for XenoPort (NASDAQ:XNPT) (?)
Ratings Breakdown: 1 Sell Rating(s), 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $7.00 (0.14% downside)

Analysts' Ratings History for XenoPort (NASDAQ:XNPT)
Show:
DateFirmActionRatingPrice TargetActions
5/24/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/19/2016Credit SuisseInitiated CoverageUnderperform$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/15/2015RBC CapitalReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for XenoPort (NASDAQ:XNPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/5/2016Q116($0.21)($0.23)$14.24 million$14.12 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.31)($0.21)$13.74 million$14.07 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.38)($0.38)$11.77 million$11.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.32)($0.39)$9.77 million$8.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.29)($0.33)$8.50 million$7.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2015Q414($0.34)($0.28)$7.10 million$7.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314($0.36)$0.13$6.30 million$31.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.33)($0.31)$4.38 million$5.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.32)($0.36)$3.86 million$3.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/20/2014Q413($0.45)($0.40)$3.35 million$2.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2013Q313($0.51)($0.39)$3.03 million$2.52 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013($0.53)($0.51)$1.74 million$2.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2013Q1 2013($0.43)($0.50)$1.20 million$4.59 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2013Q4 2012($0.42)$0.07$1.02 million$0.49 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/24/2012Q312($0.43)($0.41)$2.26 million$0.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2012($0.39)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2012($0.22)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/14/2012($0.39)($0.48)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2011($0.44)($0.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/3/2011($0.23)$0.55ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011($0.49)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/16/2011($0.62)($0.47)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for XenoPort (NASDAQ:XNPT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.26)($0.26)($0.26)
Q2 20161($0.24)($0.24)($0.24)
Q3 20161($0.18)($0.18)($0.18)
Q4 20161($0.17)($0.17)($0.17)
(Data provided by Zacks Investment Research)
Dividend History for XenoPort (NASDAQ:XNPT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for XenoPort (NASDAQ:XNPT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/19/2016James E FlynnInsiderBuy20,973$3.99$83,682.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2016James E FlynnInsiderBuy4,883,761$3.87$18,900,155.07View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016James E FlynnInsiderBuy346,417$4.09$1,416,845.53View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Ronald W BarrettCEOSell12,500$7.00$87,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Ronald W BarrettCEOSell12,500$7.20$90,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Ronald W BarrettCEOSell12,500$7.00$87,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Wendall WierengaDirectorBuy5,000$5.63$28,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Gregory T BatesSVPSell14,166$8.35$118,286.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Ronald W BarrettCEOSell7,015$8.36$58,645.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2014Gianna M BoskoSVPSell60,000$8.45$507,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2014Gregory T BatesSVPSell5,612$5.26$29,519.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2014John Gordon FreundDirectorBuy12,500$3.93$49,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014Cathy FriedmanDirectorBuy2,600$3.92$10,192.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2014John Gordon FreundDirectorBuy15,000$3.73$55,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2014Ronald W BarrettCEOBuy2,600$3.75$9,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014Paul BernsDirectorSell2,500$3.66$9,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/24/2014Paul BernsDirectorSell2,500$4.30$10,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2013Gregory T BatesSVPSell7,500$5.35$40,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2013Ernest MarioDirectorBuy20,000$5.49$109,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/9/2012Ernest MarioDirectorBuy10,000$8.50$85,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for XenoPort (NASDAQ:XNPT)
DateHeadline
06/27/16 07:06 PMInvestor News: Lawsuit against Buyout of XenoPort, Inc. (NASDAQ:XNPT) filed - GroundReport
06/24/16 07:21 PMXenoport, Inc. (NASDAQ:XNPT) went up 0.29%: Chiasma, Inc. (NASDAQ:CHMA), United Technologies Corporation ... - KC Register
06/23/16 08:10 PMAnalytical Report: Xenoport, Inc. (NASDAQ:XNPT) - iStreetWire
06/22/16 05:52 PMWhat Brexit Vote Could Mean for U.S. 2016 Election -
06/22/16 04:29 AMLawsuit for Investors in XenoPort, Inc. (NASDAQ:XNPT) in Effort to Halt Acquisition Filed - Digital Journal
06/21/16 06:48 PMLawsuit for Investors in XenoPort, Inc. (NASDAQ:XNPT) in Effort to Halt Acquisition Filed
06/21/16 11:08 AMArbor Pharmaceuticals, LLC -- Moody's Assigns B1 CFR to Arbor Pharmaceuticals; Stable Outlook -
06/18/16 04:40 AMXenoPort, Inc. (NASDAQ:XNPT) Current Analyst Ratings - Fiscal Standard
06/16/16 05:30 AMArbor Pharmaceuticals and XenoPort Announce the Expiration of the HSR Act Waiting Period - [Business Wire] - Arbor Pharmaceuticals, LLC and XenoPort, Inc. announced today that the waiting period has expired under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to the previously announced tender offer by Arbor’s wholly owned subsidiary, AP Acquisition Sub, Inc.
06/07/16 07:41 PMInvestor News: Buyout of XenoPort, Inc. (NASDAQ:XNPT) faces Investigation over possible Breaches Of Fiduciary Duties
06/06/16 07:55 AMSurging Earnings Estimates Signal Good News for Xenoport (XNPT) -
06/04/16 08:04 AMWhy Xenoport, Inc. Stock Jumped 61.1% in May -
06/03/16 08:09 PMTakeover of XenoPort, Inc. (NASDAQ:XNPT) Under Investigation for Investors Concerning Potential Wrongdoing
06/02/16 07:58 PMBuy, Sell Or Hold Rating For XenoPort, Inc. (NASDAQ:XNPT)? - Share Trading News - Buy, Sell Or Hold Rating For XenoPort, Inc. (NASDAQ:XNPT)?Share Trading NewsXenoPort, Inc. has a 50 day moving average of 5.01 and a 200 day moving average of 5.02. The stock's market capitalization is 449.13M, it has a 52-week low of 3.35 and a 52-week high of 7.86. The share price of the company (NASDAQ:XNPT) was up ...and more »
05/31/16 10:20 AMOverbuying Stock in the Spotlight: XenoPort, Inc. (NASDAQ:XNPT) - The Point Review - The Point ReviewOverbuying Stock in the Spotlight: XenoPort, Inc. (NASDAQ:XNPT)The Point ReviewThe relative strength index (RSI), one of the most popular technical indicators, is computed on the basis of the speed and direction of a stock's price movement. The RSI value will always move between 0 and 100; the value will be 0 if the stock falls ...
05/28/16 10:41 AMArmistice Capital LLC Increased Xenoport INC (NASDAQ:XNPT) by $7.06 Million as Shares Declined - CCH Daily News - Armistice Capital LLC Increased Xenoport INC (NASDAQ:XNPT) by $7.06 Million as Shares DeclinedCCH Daily NewsArmistice Capital Llc increased its stake in Xenoport Inc (NASDAQ:XNPT) by 163.52% based on its latest 2016Q1 regulatory filing with the SEC. Armistice Capital Llc bought 1.77M shares as the company's stock declined 14.58% while stock markets rallied.and more »
05/27/16 09:13 PMSHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of XenoPort, Inc. - XNPT - [Accesswire] - BALA CYNWYD, PA / ACCESSWIRE / May 27, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of XenoPort, Inc. ("XenoPort" ...
05/27/16 11:46 AMStocks Update: Rock Creek Pharmaceuticals, Inc. (NASDAQ:RCPI) , XenoPort, Inc. (NASDAQ:XNPT) - Is stories - Is storiesStocks Update: Rock Creek Pharmaceuticals, Inc. (NASDAQ:RCPI) , XenoPort, Inc. (NASDAQ:XNPT)Is storiesRock Creek Pharmaceuticals, Inc. (NASDAQ:RCPI) decreased -9.605% to $0.016 while traded 20 million shares on 5/26/2016. The stock price negotiated for value between $0.014 to $0.023 in recent trading session. During the past 52 weeks, the stock's ...and more »
05/26/16 03:16 PMXENOPORT SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Xenoport, Inc. (XNPT) Over the Proposed Sale of the Company to Arbor Pharmaceuticals, LLC - [Business Wire] - Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Xenoport, Inc.
05/26/16 10:50 AMFirst Majestic Silver Corp (NYSE:AG), XenoPort, Inc. (NASDAQ:XNPT) - NYSE Journal (press release) - First Majestic Silver Corp (NYSE:AG), XenoPort, Inc. (NASDAQ:XNPT)NYSE Journal (press release)First Majestic Silver Corp (NYSE:AG) belongs to Basic Materials sector and Silver industry. AG stock opened its last trade at $10.40 and after floating in a range of $10.07 to $11.07, settled at $11.02. AG stock gained 5.05% in total of its share price ...and more »
05/26/16 08:30 AMThe Zacks Analyst Blog Highlights: XenoPort, Biodel and AbbVie -
05/25/16 02:12 PMINVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning Whether the Sale of XenoPort, Inc. to Arbor Pharmaceuticals, LLC for $7.03 Per Share is Fair to Shareholders -- XNPT - [PR Newswire] - NEW YORK, May 25, 2016 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased XenoPort, Inc. (NASDAQ: XNPT) stock prior to May 23, 2016 ...
05/25/16 10:44 AMArbor Pharma to Acquire XenoPort (XNPT) for $7.03/Share; Deal Valued at ~$467M - Claim your 2-week free trial to StreetInsider Premium here. Arbor Pharmaceuticals, LLC (Arbor) and XenoPort, Inc. (XenoPort) (NASDAQ: XNPT) announced today that they have signed a definitive agreement under which Arbor will acquire XenoPort for $7.03 per ...
05/25/16 10:44 AMAiling XenoPort (XNPT) Lifted on Buyout Announcement - It was announced this morning that XenoPort Inc (NASDAQ:XNPT) has agreed to be acquired for about $467 million, and the company’s share price has exploded – gaining more than 56 percent since the market open. The buyer is Arbor Pharmaceuticals LLC ...
05/25/16 10:44 AMArbor Pharmaceuticals to buy XenoPort for $467M - ... will buy XenoPort Inc. for $467 million in cash. The purchase price of $7.03 a share represents a 60 percent premium over the closing price of XenoPort shares on Friday. Santa Clara-based XenoPort (NASDAQ: XNPT) has the extended-release restless leg ...
05/25/16 10:44 AMXenoPort Inc (XNPT) Stock Skyrockets on Arbor Merger Agreement - XenoPort, Inc. (NASDAQ:XNPT) shares skyrocketed as much as 56.82% during the early trading hours today, after the company announced that it is to be acquired by Arbor Pharmaceuticals. XNPT stock is currently up over 50%. The pharmaceutical company will ...
05/24/16 11:55 PMXenoPort Inc. (XNPT) is Trading Higher on Unusual Volume for May 23 - Equities.com - XenoPort Inc. (XNPT) is Trading Higher on Unusual Volume for May 23Equities.comXenoPort Inc. (XNPT) experienced unusually high volume on May. 23, as the stock gained 56.36% to a closing price of $6.88. The stock saw 54.26 million shares trade hands over the course of the day on 51,368 trades. Given that the stock's average daily ...
05/24/16 11:55 PMXenoPort Inc. (XNPT) Jumps 56.36% on May 23 - Equities.com - XenoPort Inc. (XNPT) Jumps 56.36% on May 23Equities.comXenoPort Inc. (XNPT) was among the biggest gainers on the Russell 2000 for Monday May 23 as the stock popped 56.36% to $6.88, representing a gain of $2.48 per share. Some 54.26 million shares traded hands on 51,368 trades, compared with an ...and more »
05/24/16 11:55 PMStock Overbuying in Action: XenoPort, Inc. (NASDAQ:XNPT) - The Point Review - The Point ReviewStock Overbuying in Action: XenoPort, Inc. (NASDAQ:XNPT)The Point ReviewThe relative strength index (RSI), one of the most popular technical indicators, is computed on the basis of the speed and direction of a stock's price movement. The RSI value will always move between 0 and 100; the value will be 0 if the stock falls ...and more »
05/24/16 09:10 PMSHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of XenoPort, Inc. and Encourages Investors to Contact the Firm for Additional Information - [Business Wire] - The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of XenoPort, Inc.
05/24/16 02:50 PMETF’s with exposure to XenoPort, Inc. : May 24, 2016 -
05/24/16 01:57 PMArbor Pharmaceuticals to buy XenoPort for $467 million - Privately held Arbor Pharmaceuticals will buy XenoPort Inc. for $467 million in cash. The purchase price of $7.03 a share represents a 60 percent premium over the closing price of XenoPort shares on Friday. Santa Clara-based XenoPort (NASDAQ: XNPT) has the extended-release restless leg syndrome drug Horizant on the market in the United States, and the drug is sold by partner Astellas Pharma Inc. in Japan. But a mid-stage trial of an experimental drug, called XP-23829, in the fall reported high…
05/24/16 11:31 AMSHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of XenoPort Inc. - XNPT - [PR Newswire] - NEW YORK, May 24, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XenoPort Inc. ("XenoPort" or the "Company") (NASDAQ: XNPT) (ISIN: US98411C100) ...
05/24/16 11:18 AMMonday's Market Insights: Relypsa Inc (RLYP), Seadrill Ltd (SDRL), Nanosphere, Inc. (NSPH), XenoPort, Inc. (XNPT) - Smarter Analyst - Monday's Market Insights: Relypsa Inc (RLYP), Seadrill Ltd (SDRL), Nanosphere, Inc. (NSPH), XenoPort, Inc. (XNPT)Smarter AnalystRelpysa Inc (NASDAQ:RLYP) is up over 5% after positive data from its hyperkalemia treatment, Veltassa. The company released data from analyses of studies regarding the effect of the Potassium Binding Polymer Patiromer on urine sodium excretion in ...
05/24/16 11:18 AMHealthcare Unusual Volume: Xenoport, Inc. (NASDAQ:XNPT), Cellectar Biosciences, Inc. (NASDAQ:CLRB), Rock ... - KC Register - Healthcare Unusual Volume: Xenoport, Inc. (NASDAQ:XNPT), Cellectar Biosciences, Inc. (NASDAQ:CLRB), Rock ...KC RegisterXenoport, Inc. (NASDAQ:XNPT) said that, Arbor Pharmaceuticals plans to acquire XenoPort for approximately $467 million, adding two marketed products and a pipeline of specialty drugs to the buyer's portfolio. On Monday Xenoport, Inc. (NASDAQ:XNPT) ...
05/24/16 11:18 AMInvestor's observing Biotech Stocks: XenoPort, Inc. (NASDAQ:XNPT) , Medivation, Inc. (NASDAQ:MDVN) - Is stories - Investor's observing Biotech Stocks: XenoPort, Inc. (NASDAQ:XNPT) , Medivation, Inc. (NASDAQ:MDVN)Is storiesXenoPort, Inc. (NASDAQ:XNPT) increased +56.36% to $6.88 while traded 54.28 million shares on 5/23/2016. The stock price negotiated for value between $6.87 to $6.91 in recent trading session. During the past 52 weeks, the stock's price witnessed a ...and more »
05/24/16 11:18 AMValeant Pharmaceuticals Intl (NYSE:VRX) & XenoPort, Inc. (NASDAQ:XNPT) Healthcare Stocks on the Run - Wall Street 24 - Bidness ETCValeant Pharmaceuticals Intl (NYSE:VRX) & XenoPort, Inc. (NASDAQ:XNPT) Healthcare Stocks on the RunWall Street 24On Monday, Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) lost -4.59% to $26.21. The share price is trading in a range of $26.11 – $27.67. The stock exchanged hands with 24.58 Million shares contrast to its average daily volume of 33.41 Million ...Healthcare Stocks Lure Investment- Xenoport (NASDAQ:XNPT), Valeant Pharmaceuticals International (NYSE:VRX)Seneca Globeall 49 news articles »
05/24/16 11:18 AMSummary of Analysts Rating: XenoPort, Inc. (NASDAQ:XNPT) , Teva Pharmaceutical Industries Limited (NYSE:TEVA) - Street Updates - Summary of Analysts Rating: XenoPort, Inc. (NASDAQ:XNPT) , Teva Pharmaceutical Industries Limited (NYSE:TEVA)Street UpdatesArbor Pharmaceuticals, LLC (Arbor) and XenoPort, Inc. (XNPT) reported that they have signed a definitive contract under which Arbor will acquire XenoPort for $7.03 per share in cash, or a total equity value of about $467 million. The purchase price per ...and more »
05/24/16 10:30 AMXenoport to be Acquired by Arbor Pharmaceuticals; Stock Up -
05/24/16 09:54 AMRyan & Maniskas, LLP Announces Investigation of XenoPort, Inc. - [PR Newswire] - WAYNE, Pa., May 24, 2016 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating potential claims against the board of directors of XenoPort, Inc. ("XenoPort" or the "Company") (NASDAQ: ...
05/24/16 07:15 AMXenoPort, Inc. breached its 50 day moving average in a Bullish Manner : XNPT-US : May 24, 2016 -
05/23/16 10:05 PMXenoPort, Inc. (XNPT) Stock Roars 56% on Generous Buyout - Nasdaq - Bidness ETCXenoPort, Inc. (XNPT) Stock Roars 56% on Generous BuyoutNasdaqAs for how the new owner of XNPT stock will put XenoPort's star drug to work, I wouldn't rule out the Valeant Pharmaceuticals Intl Inc ( VRX ) buy-and-raise model just yet. While politically unpopular, it wouldn't shock me in the least if the bean ...XenoPort, Inc, Inovio Pharmaceuticals Inc, Relypsa Inc: Midday Healthcare Gainers TodayBidness ETCArbor Pharma to Acquire XenoPort (XNPT) for $7.03/Share; Deal Valued at ~$467MStreetInsider.comArbor Pharma Announces Acquisition Of Xenoport At A 60% PremiumBenzingaThe Point Review -Economic Calendar -Motley Foolall 34 news articles »
05/23/16 09:25 PMSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of XenoPort, Inc. -XNPT - [PR Newswire] - BALA CYNWYD, Pa., May 23, 2016 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of XenoPort, Inc. ("XenoPort" or "the Company") (Nasdaq- XNPT-News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Arbor Pharmaceuticals, LLC. ("Arbor"). Under the terms of the transaction, XenoPort shareholders will receive only $7.03 in cash for each share of XenoPort stock they own.
05/23/16 07:58 PMBenzinga's M&A Chatter for Monday May 23, 2016 - The following are the M&A deals, rumors and chatter circulating on Wall Street for Monday May 23, 2016: Bayer Offers $122/Share in Cash to Acquire Monsanto; $62B Total Valuation The Offer:Bayer (OTC: BAYRY) announced Monday, its proposal to acquire Monsanto (NYSE: MON) for $122 per share in cash or $62 billion. This offer is based on Bayer's written proposal dated May 10, 2016. Shares of Monsanto traded over $115 in the premarket, but sold off into and through the regular session on regulatory concerns and pressure from Bayer shareholders not to proceed with the deal. Monsanto Rose 4.41% Monday to close at $106.00. Arbor Pharmaceuticals to Acquire Xenoport for $7.03/Share in Cash The Deal:Arbor Pharmaceuticals, LLC and XenoPort, Inc. (NASDAQ: XNPT) announced Monday, that they agreed that Arbor will acquire XenoPort for $7.03 per share in cash, for a total equity value of approximately $467 million. The has been unanimously approved by both company'd Boards of Directors and is expected ...Full story available on Benzinga.com
05/23/16 07:20 PMWhy Monsanto, XenoPort, and LendingClub Jumped Today - Even though the market was flat, these stocks rose substantially. Find out why.
05/23/16 04:33 PMHarwood Feffer LLP Announces Investigation of XenoPort, Inc. - [PR Newswire] - NEW YORK, May 23, 2016 /PRNewswire/ -- Harwood Feffer LLP ( www.hfesq.com ) is investigating potential claims against the board of directors of XenoPort, Inc. ("XenoPort" or the "Company") ...
05/23/16 04:00 PMXenoPort Stock Rises Nearly 60% on Takeover News -
05/23/16 02:46 PMHere's Why XenoPort (XNPT) Stock is Continuing to Surge Today -
05/23/16 02:33 PMMid-Afternoon Market Update: KLX Drops On Q1 Results; Resource America Shares Spike Higher - Toward the end of trading Monday, the Dow traded up 0.21 percent to 17,538.25 while the NASDAQ climbed 0.22 percent to 4,779.93. The S&P also rose, gaining 0.03 percent to 2,052.84. Leading and Lagging Sectors Basic materials shares gained by 0.78 percent in trading on Monday. Top gainers in the sector included Haynes International, Inc. (NASDAQ: HAYN), CF Industries Holdings, Inc. (NYSE: CF), and Valhi, Inc. (NYSE: VHI). In trading on Monday, utilities shares dropped by 0.44 percent. Meanwhile, top losers in the sector included Companhia Paranaense de Energia (ADR) (NYSE: ELP), down 4 percent, and CPFL Energia S.A. (ADR) (NYSE: CPL), down 3 percent. Top Headline XenoPort, Inc. (NASDAQ: XNPT) entered into definitive agreement with privately-owned Arbor Pharmaceuticals in which it will be acquired for $7.03 per share in cash, valuing the company at approximately $467 million. The acquisition price represents a premium ...Full story available on Benzinga.com
05/23/16 02:19 PMXENOPORT, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by Arbor Pharmaceuticals, LLC May Be Unfair to Shareholders - [Business Wire] - Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of XenoPort, Inc.
About XenoPort

XenoPort logoXenoPort, Inc. is a biopharmaceutical company. The Company is focused on commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets in the United States. The Company's segment is the development and commercialization of product candidates for the treatment of neurological and other disorders. Its development-stage product candidates include XP23829, XP21279 and arbaclofen placarbil. HORIZANT has been approved by the United States Food and Drug Administration for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. XP23829 is a fumaric acid ester compound and a prodrug of metabolite monomethyl fumarate being developed for the treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or patients with relapsing forms of multiple sclerosis. XP21279 is a Transported Prodrug of levodopa being developed for the treatment for patients with idiopathic Parkinson's disease.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: XNPT
  • CUSIP: 98411C10
Key Metrics:
  • Previous Close: $7.01
  • 50 Day Moving Average: $6.22
  • 200 Day Moving Average: $5.15
  • P/E Ratio: N/A
  • P/E Growth: -2.86
  • Market Cap: $445.32M
  • Current Quarter EPS Consensus Estimate: $-0.49 EPS
Additional Links:
XenoPort (NASDAQ:XNPT) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha